{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["breast cancer", "epithelial-mesenchymal transition", "oxymatrine", "\u03b1\u2164\u03b23 integrin"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "31496729", "DateRevised": {"Year": "2022", "Month": "04", "Day": "10"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "08", "Day": "08"}], "Language": ["eng"], "ELocationID": ["10.2147/OTT.S209056"], "Journal": {"ISSN": "1178-6930", "JournalIssue": {"Volume": "12", "PubDate": {"Year": "2019"}}, "Title": "OncoTargets and therapy", "ISOAbbreviation": "Onco Targets Ther"}, "ArticleTitle": "Oxymatrine reverses epithelial-mesenchymal transition in breast cancer cells by depressing \u03b1<sub>\u2164</sub>\u03b2<sub>3</sub> integrin/FAK/PI3K/Akt signaling activation.", "Pagination": {"StartPage": "6253", "EndPage": "6265", "MedlinePgn": "6253-6265"}, "Abstract": {"AbstractText": ["Oxymatrine, an alkaloid extracted from the Chinese herb <i>Sophora flavescens</i> Aiton, possesses anti-inflammatory, anti-immune, anti-hepatic fibrosis, and anti-cancer properties. However, the effects of oxymatrine on epithelial-mesenchymal transition (EMT) of breast cancer cells are still unclear.", "The present study was performed to investigate whether oxymatrine reverses EMT in breast cancer cells and to explore the underlying molecular mechanisms.", "MTT assay was performed to evaluate cell viability. Wound-healing assay and transwell chamber assay were used to assess cell migration and invasion, respectively. Immunofluorescence and Western blot were used to study the expression of EMT-related molecules and \u03b1<sub>\u2164</sub>\u03b2<sub>3</sub> integrin/focal adhesion kinase (FAK)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling transduction. Fibronectin, a physiologic ligand of \u03b1<sub>\u2164</sub>\u03b2<sub>3</sub>\u00a0integrin, was used to stimulate \u03b1<sub>\u2164</sub>\u03b2<sub>3</sub> integrin signaling.", "Our results demonstrated that oxymatrine effectively suppressed the viability of MDA-MB-231 and 4T1 breast cancer cells, and oxymatrine showed less cytotoxicity on normal breast mammary epithelial MCF-10A cells. In addition, oxymatrine reversed EMT in the MDA-MB-231 and 4T1 cells at nontoxic concentrations. Oxymatrine significantly inhibited cell migration and invasion, downregulated the expression of N-cadherin, vimentin, and Snail in MDA-MB-231 and 4T1 cells, but upregulated the expression of E-cadherin in 4T1 cells. The mechanism revealed that oxymatrine decreased the expression of \u03b1<sub>\u2164</sub> and \u03b2<sub>3</sub> integrin and their co-localization. It also inhibited \u03b1<sub>\u2164</sub>\u03b2<sub>3</sub> integrin downstream activation by suppressing the phosphorylation of FAK, PI3K, and Akt. Furthermore, oxymatrine prevented fibronectin-induced EMT and \u03b1<sub>\u2164</sub>\u03b2<sub>3</sub> integrin/FAK/PI3K/Akt signaling activation.", "Our results revealed that oxymatrine effectively reversed EMT in breast cancer cells by depressing \u03b1<sub>\u2164</sub>\u03b2<sub>3</sub> integrin/FAK/PI3K/Akt signaling. Thus, oxymatrine could be a potential therapeutic candidate with anti-metastatic potential for the treatment of breast cancer."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Department of Pharmacology of Materia Medica (The State Key Laboratory of Functions and Applications of Medicinal Plants, The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Union Key Laboratory of Guiyang City-Guizhou Medical University, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}], "LastName": "Chen", "ForeName": "Yan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Department of Pharmacology of Materia Medica (The State Key Laboratory of Functions and Applications of Medicinal Plants, The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "Department of Pharmacology, Qiannan Medical College For Nationalities, Duyun, Guizhou, People's Republic of China."}], "LastName": "Chen", "ForeName": "Lin", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Department of Pharmacology of Materia Medica (The State Key Laboratory of Functions and Applications of Medicinal Plants, The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}], "LastName": "Zhang", "ForeName": "Jing-Yu", "Initials": "JY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Department of Pharmacology of Materia Medica (The State Key Laboratory of Functions and Applications of Medicinal Plants, The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}], "LastName": "Chen", "ForeName": "Zong-Yue", "Initials": "ZY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Department of Pharmacology of Materia Medica (The State Key Laboratory of Functions and Applications of Medicinal Plants, The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}], "LastName": "Liu", "ForeName": "Ting-Ting", "Initials": "TT"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Department of Pharmacology of Materia Medica (The State Key Laboratory of Functions and Applications of Medicinal Plants, The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Union Key Laboratory of Guiyang City-Guizhou Medical University, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}], "LastName": "Zhang", "ForeName": "Yan-Yan", "Initials": "YY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Department of Pharmacology of Materia Medica (The State Key Laboratory of Functions and Applications of Medicinal Plants, The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Union Key Laboratory of Guiyang City-Guizhou Medical University, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}], "LastName": "Fu", "ForeName": "Ling-Yun", "Initials": "LY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Department of Pharmacology of Materia Medica (The State Key Laboratory of Functions and Applications of Medicinal Plants, The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}], "LastName": "Fan", "ForeName": "Shuang-Qin", "Initials": "SQ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Union Key Laboratory of Guiyang City-Guizhou Medical University, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}], "LastName": "Zhang", "ForeName": "Min-Qin", "Initials": "MQ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Department of Pharmacology of Materia Medica (The State Key Laboratory of Functions and Applications of Medicinal Plants, The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Union Key Laboratory of Guiyang City-Guizhou Medical University, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}], "LastName": "Gan", "ForeName": "Shi-Quan", "Initials": "SQ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Department of Pharmacology of Materia Medica (The State Key Laboratory of Functions and Applications of Medicinal Plants, The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Union Key Laboratory of Guiyang City-Guizhou Medical University, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}], "LastName": "Zhang", "ForeName": "Nen-Ling", "Initials": "NL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Department of Pharmacology of Materia Medica (The State Key Laboratory of Functions and Applications of Medicinal Plants, The High Educational Key Laboratory of Guizhou Province for Natural Medicinal Pharmacology and Druggability), School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Union Key Laboratory of Guiyang City-Guizhou Medical University, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou, People's Republic of China."}], "LastName": "Shen", "ForeName": "Xiang-Chun", "Initials": "XC"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Onco Targets Ther", "NlmUniqueID": "101514322", "ISSNLinking": "1178-6930"}, "CoiStatement": "The authors report no conflicts of interest in this work."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Arora R, Yates C, Gary BD, et al. Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer. PLoS One. 2014;9(6):e98370. doi:10.1371/journal.pone.0098370", "ArticleIdList": ["10.1371/journal.pone.0098370", "PMC4045585", "24896091"]}, {"Citation": "Kozlowski J, Kozlowska A, Kocki J. Breast cancer metastasis - insight into selected molecular mechanisms of the phenomenon. Postepy Hig Med Dosw (Online). 2015;69:447\u2013451.", "ArticleIdList": ["25897105"]}, {"Citation": "Bonotto M, Gerratana L, Poletto E, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014;19(6):608\u2013615. doi:10.1634/theoncologist.2014-0002", "ArticleIdList": ["10.1634/theoncologist.2014-0002", "PMC4041678", "24794159"]}, {"Citation": "Kiely BE, Soon YY, Tattersall MH, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol. 2011;29(4):456\u2013463. doi:10.1200/JCO.2010.30.2174", "ArticleIdList": ["10.1200/JCO.2010.30.2174", "21189397"]}, {"Citation": "Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420\u20131428. doi:10.1172/JCI39104", "ArticleIdList": ["10.1172/JCI39104", "PMC2689101", "19487818"]}, {"Citation": "Savagner P. Epithelial-mesenchymal transitions: from cell plasticity to concept elasticity. Curr Top Dev Biol. 2015;112:273\u2013300. doi:10.1016/bs.ctdb.2014.11.021", "ArticleIdList": ["10.1016/bs.ctdb.2014.11.021", "25733143"]}, {"Citation": "Takada Y, Ye X, Simon S. The integrins. Genome Biol. 2007;8(5):215. doi:10.1186/gb-2007-8-5-r81", "ArticleIdList": ["10.1186/gb-2007-8-5-r81", "PMC1929136", "17543136"]}, {"Citation": "Giancotti FG, Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol. 2003;19:173\u2013206. doi:10.1146/annurev.cellbio.19.031103.133334", "ArticleIdList": ["10.1146/annurev.cellbio.19.031103.133334", "14570568"]}, {"Citation": "Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005;6(1):56\u201368. doi:10.1038/nrm1549", "ArticleIdList": ["10.1038/nrm1549", "15688067"]}, {"Citation": "Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9\u201322. doi:10.1038/nrc2748", "ArticleIdList": ["10.1038/nrc2748", "PMC4383089", "20029421"]}, {"Citation": "Liapis H, Flath A, Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol. 1996;5(2):127\u2013135.", "ArticleIdList": ["8727100"]}, {"Citation": "Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res. 1998;4(11):2625\u20132634.", "ArticleIdList": ["9829725"]}, {"Citation": "Felding-Habermann B, O\u2019Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A. 2001;98(4):1853\u20131858. doi:10.1073/pnas.98.4.1853", "ArticleIdList": ["10.1073/pnas.98.4.1853", "PMC29346", "11172040"]}, {"Citation": "Oh S, Kim H, Nam K, Shin I. Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells. BMB Rep. 2017;50(3):132\u2013137. doi:10.5483/bmbrep.2017.50.3.189", "ArticleIdList": ["10.5483/bmbrep.2017.50.3.189", "PMC5422025", "27931517"]}, {"Citation": "Hill BS, Sarnella A, Capasso D, et al. Therapeutic potential of a novel alphavbeta(3) antagonist to hamper the aggressiveness of mesenchymal triple negative breast cancer sub-type. Cancers (Basel). 2019;11(2):139. doi:10.3390/cancers11020139", "ArticleIdList": ["10.3390/cancers11020139", "PMC6406933", "30682838"]}, {"Citation": "Mori S, Kodaira M, Ito A, et al. Enhanced expression of integrin alphavbeta3 induced by TGF-beta is required for the enhancing effect of Fibroblast Growth Factor 1 (FGF1) in TGF-beta-induced Epithelial-Mesenchymal Transition (EMT) in mammary epithelial cells. PLoS One. 2015;10(9):e0137486. doi:10.1371/journal.pone.0137486", "ArticleIdList": ["10.1371/journal.pone.0137486", "PMC4559424", "26334633"]}, {"Citation": "Luo BP, Luo J, Hu YB, Yao XW, Wu FH. Cyclin D1b splice variant promotes alphavbeta3-mediated EMT induced by LPS in breast cancer cells. Curr Med Sci. 2018;38(3):467\u2013472. doi:10.1007/s11596-018-1902-5", "ArticleIdList": ["10.1007/s11596-018-1902-5", "30074214"]}, {"Citation": "He M, Wu Y, Wang M, Chen W, Yuan W, Jiang J. The clinical value of oxymatrine in preventing lamivudine induced YMDD mutation: a meta-analysis. Evid Based Complement Alternat Med. 2015;2015:971616. doi:10.1155/2015/971616", "ArticleIdList": ["10.1155/2015/971616", "PMC4609836", "26508988"]}, {"Citation": "Wang W, You RL, Qin WJ, et al. Anti-tumor activities of active ingredients in compound kushen injection. Acta Pharmacol Sin. 2015;36(6):676\u2013679. doi:10.1038/aps.2015.24", "ArticleIdList": ["10.1038/aps.2015.24", "PMC4594177", "25982630"]}, {"Citation": "Liu Y, Xu Y, Ji W, et al. Anti-tumor activities of matrine and oxymatrine: literature review. Tumour Biol. 2014;35(6):5111\u20135119. doi:10.1007/s13277-014-1680-z", "ArticleIdList": ["10.1007/s13277-014-1680-z", "24526416"]}, {"Citation": "Wu J, Cai Y, Li M, Zhang Y, Li H, Tan Z. Oxymatrine promotes S-phase arrest and inhibits cell proliferation of human breast cancer cells in vitro through mitochondria-mediated apoptosis. Biol Pharm Bull. 2017;40(8):1232\u20131239. doi:10.1248/bpb.b17-00010", "ArticleIdList": ["10.1248/bpb.b17-00010", "28769005"]}, {"Citation": "Zhang Y, Piao B, Zhang Y, et al. Oxymatrine diminishes the side population and inhibits the expression of beta-catenin in MCF-7 breast cancer cells. Med Oncol. 2011;28(Suppl 1):S99\u2013S107. doi:10.1007/s12032-010-9721-y", "ArticleIdList": ["10.1007/s12032-010-9721-y", "21069479"]}, {"Citation": "Kia V, Mortazavi Y, Paryan M, Biglari A, Mohammadi-Yeganeh S. Exosomal miRNAs from highly metastatic cells can induce metastasis in non-metastatic cells. Life Sci. 2019;220:162\u2013168. doi:10.1016/j.lfs.2019.01.057", "ArticleIdList": ["10.1016/j.lfs.2019.01.057", "30721706"]}, {"Citation": "Tao K, Fang M, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 2008;8:228. doi:10.1186/1471-2407-8-172", "ArticleIdList": ["10.1186/1471-2407-8-172", "PMC2529338", "18691423"]}, {"Citation": "Oudart JB, Doue M, Vautrin A, et al. The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through alphavbeta3 integrin interaction. Oncotarget. 2016;7(2):1516\u20131528. doi:10.18632/oncotarget.6399", "ArticleIdList": ["10.18632/oncotarget.6399", "PMC4811477", "26621838"]}, {"Citation": "Anderson RL, Balasas T, Callaghan J, et al. A framework for the development of effective anti-metastatic agents. Nat Rev Clin Oncol. 2019;16(3):185\u2013204. doi:10.1038/s41571-018-0134-8", "ArticleIdList": ["10.1038/s41571-018-0134-8", "PMC7136167", "30514977"]}, {"Citation": "Seabrooks L, Hu L. Insects: an underrepresented resource for the discovery of biologically active natural products. Acta Pharm Sin B. 2017;7(4):409\u2013426. doi:10.1016/j.apsb.2017.05.001", "ArticleIdList": ["10.1016/j.apsb.2017.05.001", "PMC5518667", "28752026"]}, {"Citation": "Song WJ, Luo J, Wu T, Yao SK. Oral oxymatrine preparation for chronic hepatitis B: a systematic review of randomized controlled trials. Chin J Integr Med. 2016;22(2):141\u2013149. doi:10.1007/s11655-015-2143-0", "ArticleIdList": ["10.1007/s11655-015-2143-0", "26016455"]}, {"Citation": "Lu ML, Xiang XH, Xia SH. Potential signaling pathways involved in the clinical application of oxymatrine. Phytother Res. 2016;30(7):1104\u20131112. doi:10.1002/ptr.5632", "ArticleIdList": ["10.1002/ptr.5632", "27165263"]}, {"Citation": "Cha Y, Erez T, Reynolds IJ, et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018;175(2):168\u2013180. doi:10.1111/bph.13798", "ArticleIdList": ["10.1111/bph.13798", "PMC5758385", "28369768"]}, {"Citation": "Banyard J, Bielenberg DR. The role of EMT and MET in cancer dissemination. Connect Tissue Res. 2015;56(5):403\u2013413. doi:10.3109/03008207.2015.1060970", "ArticleIdList": ["10.3109/03008207.2015.1060970", "PMC4780319", "26291767"]}, {"Citation": "van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65(23):3756\u20133788. doi:10.1007/s00018-008-8281-1", "ArticleIdList": ["10.1007/s00018-008-8281-1", "18726070"]}, {"Citation": "Zhou J, Tao D, Xu Q, Gao Z, Tang D. Expression of E-cadherin and vimentin in oral squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(3):3150\u20133154.", "ArticleIdList": ["PMC4440141", "26045832"]}, {"Citation": "Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u2013196. doi:10.1038/nrm3758", "ArticleIdList": ["10.1038/nrm3758", "PMC4240281", "24556840"]}, {"Citation": "Gheldof A, Berx G. Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci. 2013;116:317\u2013336. doi:10.1016/B978-0-12-394311-8.00014-5", "ArticleIdList": ["10.1016/B978-0-12-394311-8.00014-5", "23481201"]}, {"Citation": "Philippe CL. Therapeutic value of an integrin antagonist in prostate cancer. Curr Drug Targets. 2016;17(3):321\u2013327.", "ArticleIdList": ["26648077"]}, {"Citation": "Cheng C, Komljenovic D, Pan L, Dimitrakopoulou-Strauss A, Strauss L, Bauerle T. Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG. Hell J Nucl Med. 2011;14(1):15\u201320.", "ArticleIdList": ["21512659"]}, {"Citation": "Wu YJ, Muldoon LL, Gahramanov S, Kraemer DF, Marshall DJ, Neuwelt EA. Targeting alphaV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. J Neurooncol. 2012;110(1):27\u201336. doi:10.1007/s11060-012-0942-0", "ArticleIdList": ["10.1007/s11060-012-0942-0", "PMC3726254", "22842979"]}, {"Citation": "Wu YJ, Pagel MA, Muldoon LL, Fu R, Neuwelt EA. High alphav integrin level of cancer cells is associated with development of brain metastasis in athymic rats. Anticancer Res. 2017;37(8):4029\u20134040. doi:10.21873/anticanres.11788", "ArticleIdList": ["10.21873/anticanres.11788", "PMC5800856", "28739685"]}, {"Citation": "Benito-Jardon M, Klapproth S, Gimeno LI, et al. The fibronectin synergy site re-enforces cell adhesion and mediates a crosstalk between integrin classes. Elife. 2017;6:e22264.", "ArticleIdList": ["PMC5279944", "28092265"]}, {"Citation": "Oberhauser AF, Badilla-Fernandez C, Carrion-Vazquez M, Fernandez JM. The mechanical hierarchies of fibronectin observed with single-molecule AFM. J Mol Biol. 2002;319(2):433\u2013447. doi:10.1016/S0022-2836(02)00306-6", "ArticleIdList": ["10.1016/S0022-2836(02)00306-6", "12051919"]}, {"Citation": "Burridge K. Focal adhesions: a personal perspective on a half century of progress. Febs J. 2017;284(20):3355\u20133361. doi:10.1111/febs.14195", "ArticleIdList": ["10.1111/febs.14195", "PMC5643231", "28796323"]}, {"Citation": "Flamini MI, Uzair ID, Pennacchio GE, et al. Thyroid hormone controls breast cancer cell movement via integrin alphaV/beta3/SRC/FAK/PI3-Kinases. Horm Cancer. 2017;8(1):16\u201327. doi:10.1007/s12672-016-0280-3", "ArticleIdList": ["10.1007/s12672-016-0280-3", "PMC10355986", "28050799"]}, {"Citation": "Jiang WG, Sanders AJ, Katoh M, et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol. 2015;35(Suppl):S244\u2013S275. doi:10.1016/j.semcancer.2015.03.008", "ArticleIdList": ["10.1016/j.semcancer.2015.03.008", "25865774"]}, {"Citation": "Luo J, Yao JF, Deng XF, et al. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin alphavbeta3 and activating FAK/PI3K/AKT signaling. J Exp Clin Cancer Res. 2018;37(1):23. doi:10.1186/s13046-018-0694-6", "ArticleIdList": ["10.1186/s13046-018-0694-6", "PMC5807756", "29426357"]}, {"Citation": "Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V, Chen X. Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment. Recent Pat Anticancer Drug Discov. 2007;2(2):143\u2013158.", "ArticleIdList": ["18221059"]}]}], "History": [{"Year": "2019", "Month": "3", "Day": "17"}, {"Year": "2019", "Month": "7", "Day": "17"}, {"Year": "2019", "Month": "9", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "9", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "9", "Day": "10", "Hour": "6", "Minute": "1"}, {"Year": "2019", "Month": "8", "Day": "8"}], "PublicationStatus": "epublish", "ArticleIdList": ["31496729", "PMC6691185", "10.2147/OTT.S209056", "209056"]}}]}